Early and late effects of pharmacological ALK inhibition on the neuroblastoma transcriptome

Shana Claeys; Geertrui Denecker; Robrecht Cannoodt; Candy Kumps; Kaat Durinck; Frank Speleman; Katleen De Preter

doi:10.18632/oncotarget.22423

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Early and late effects of pharmacological ALK inhibition on the neuroblastoma transcriptome

Shana Claeys, Geertrui Denecker, Robrecht Cannoodt, Candy Kumps, Kaat Durinck, Frank Speleman and Katleen De Preter _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:106820-106832. https://doi.org/10.18632/oncotarget.22423

Metrics: PDF 1548 views | HTML 1922 views | ?

Abstract

Shana Claeys1,2, Geertrui Denecker1,2, Robrecht Cannoodt1,2,3,4,5, Candy Kumps1,6, Kaat Durinck1,2, Frank Speleman1,2 and Katleen De Preter1,2

1Center for Medical Genetics, Ghent University, Ghent, Belgium

2Cancer Research Institute Ghent, Ghent University, Ghent, Belgium

3Bioinformatics Institute Ghent From Nucleotides to Networks, Ghent, Belgium

4Data Mining and Modelling for Biomedicine group, VIB Inflammation Research Center, Ghent, Belgium

5Department of Respiratory Medicine, Ghent University, Ghent, Belgium

6Department of Uro-Gynaecology, Ghent University Hospital, Ghent, Belgium

Correspondence to:

Katleen De Preter, email: [email protected]

Keywords: neuroblastoma; ALK; ALK inhibition; ALK signaling; dynamic

Received: July 28, 2017 Accepted: October 17, 2017 Published: November 06, 2017

ABSTRACT

Background: Neuroblastoma is an aggressive childhood malignancy of the sympathetic nervous system. Despite multi-modal therapy, survival of high-risk patients remains disappointingly low, underscoring the need for novel treatment strategies. The discovery of ALK activating mutations opened the way to precision treatment in a subset of these patients. Previously, we investigated the transcriptional effects of pharmacological ALK inhibition on neuroblastoma cell lines, six hours after TAE684 administration, resulting in the 77-gene ALK signature, which was shown to gradually decrease from 120 minutes after TAE684 treatment, to gain deeper insight into the molecular effects of oncogenic ALK signaling.

Aim: Here, we further dissected the transcriptional dynamic profiles of neuroblastoma cells upon TAE684 treatment in a detailed timeframe of ten minutes up to six hours after inhibition, in order to identify additional early targets for combination treatment.

Results: We observed an unexpected initial upregulation of positively regulated MYCN target genes following subsequent downregulation of overall MYCN activity. In addition, we identified adrenomedullin (ADM), previously shown to be implicated in sunitinib resistance, as the earliest response gene upon ALK inhibition.

Conclusions: We describe the early and late effects of ALK inhibitor TAE684 treatment on the neuroblastoma transcriptome. The observed unexpected upregulation of ADM warrants further investigation in relation to putative ALK resistance in neuroblastoma patients currently undergoing ALK inhibitor treatment.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 22423

Publication Alerts

Research Papers:

Early and late effects of pharmacological ALK inhibition on the neuroblastoma transcriptome

Abstract